BRPI0409148A - combinação de um imunomodulador de células-t de macrolìdeo e um calciferol para o tratamento de doenças de pele ou de doença inflamatória no intestino - Google Patents

combinação de um imunomodulador de células-t de macrolìdeo e um calciferol para o tratamento de doenças de pele ou de doença inflamatória no intestino

Info

Publication number
BRPI0409148A
BRPI0409148A BRPI0409148-5A BRPI0409148A BRPI0409148A BR PI0409148 A BRPI0409148 A BR PI0409148A BR PI0409148 A BRPI0409148 A BR PI0409148A BR PI0409148 A BRPI0409148 A BR PI0409148A
Authority
BR
Brazil
Prior art keywords
calciferol
macrolide
treatment
combination
disease
Prior art date
Application number
BRPI0409148-5A
Other languages
English (en)
Inventor
Maximilian Grassberger
Stefan Hirsch
Friedrich Karl Mayer
Josef Gottfried Meingassner
Carle Paul
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409148A publication Critical patent/BRPI0409148A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO DE UM IMUNOMODULADOR DE CéLULAS-T DE MACROLìDEO E UM CALCIFEROL PARA O TRATAMENTO DE DOENçAS DA PELE OU DE DOENçA INFLAMATóRIA NO INTESTINO". A presente invenção refere-se a combinações sinergísticas de um imunomodulador ou imunossupressor de células T de macrolídeo tal como 33-epicloro-33-desoxiascomicina e um calciferol, tais como calcipotriol ou tacalcitol são proporcionadas, as quais são usadas, em particular, no tratamento de doenças dermatológicas tais como dermatite atópica, acne e psoríase ou de doença inflamatória do intestino (IBD).
BRPI0409148-5A 2003-04-04 2004-04-02 combinação de um imunomodulador de células-t de macrolìdeo e um calciferol para o tratamento de doenças de pele ou de doença inflamatória no intestino BRPI0409148A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307865.6A GB0307865D0 (en) 2003-04-04 2003-04-04 Pharmaceutical composition
PCT/EP2004/003512 WO2004087170A1 (en) 2003-04-04 2004-04-02 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BRPI0409148A true BRPI0409148A (pt) 2006-05-09

Family

ID=9956228

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409148-5A BRPI0409148A (pt) 2003-04-04 2004-04-02 combinação de um imunomodulador de células-t de macrolìdeo e um calciferol para o tratamento de doenças de pele ou de doença inflamatória no intestino

Country Status (13)

Country Link
US (1) US20060106003A1 (pt)
EP (1) EP1613330A1 (pt)
JP (1) JP2006522058A (pt)
CN (1) CN1761470A (pt)
AU (1) AU2004226820B2 (pt)
BR (1) BRPI0409148A (pt)
CA (1) CA2519096A1 (pt)
GB (1) GB0307865D0 (pt)
IS (1) IS8092A (pt)
MX (1) MXPA05010702A (pt)
NO (1) NO20055182L (pt)
RS (1) RS20050668A (pt)
WO (1) WO2004087170A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087526A1 (en) * 2020-10-23 2022-04-28 Massachusetts Institute Of Technology Methods and compositions for differentiating stem cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB9004544D0 (en) * 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP3506474B2 (ja) * 1994-01-07 2004-03-15 帝人株式会社 安定性の向上した乾癬治療剤
JP3839502B2 (ja) * 1994-03-03 2006-11-01 帝人株式会社 湿疹・皮膚炎群治療剤
CA2270373A1 (en) * 1996-10-31 1998-05-07 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
DE19744127B4 (de) * 1997-10-01 2006-10-05 Schering Ag Neue Vitamin D-Derivate mit Cyclopropylringen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
CA2436195A1 (en) * 2001-02-09 2002-08-22 Kosan Biosciences, Inc. Laulimalide derivatives
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
EP1392323B1 (en) * 2001-05-22 2008-10-08 Bioxell S.p.a. Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject

Also Published As

Publication number Publication date
EP1613330A1 (en) 2006-01-11
RS20050668A (sr) 2007-11-15
JP2006522058A (ja) 2006-09-28
GB0307865D0 (en) 2003-05-14
CN1761470A (zh) 2006-04-19
IS8092A (is) 2005-10-27
WO2004087170A1 (en) 2004-10-14
MXPA05010702A (es) 2005-12-12
AU2004226820B2 (en) 2008-02-21
CA2519096A1 (en) 2004-10-14
NO20055182D0 (no) 2005-11-03
NO20055182L (no) 2006-01-03
AU2004226820A1 (en) 2004-10-14
WO2004087170B1 (en) 2004-11-25
US20060106003A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2009061916A3 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
GB2423928A (en) Methods and compositions for treating pain
WO2005102252A3 (de) Haut- und/oder haarmittel enthaltend verbindungen mit isoprenoider struktur
MY147247A (en) Organic compounds and their uses
EP2144608A4 (en) SUN PROTECTION COMPOSITIONS AND METHODS
BR0318498A (pt) composições terapêuticas à base de porìfero para o tratamento e a prevenção de doenças da pele
WO2005051341A3 (en) Topical cosmetic composition
MXPA05010708A (es) Composicion farmaceutica que comprende un inmunosupresor para utilizarse en el tratamiento de enfermedades de la piel.
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2008058210A3 (en) Local administration of gallium compositions to treat pain
MX2010009488A (es) Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.
WO2007084625A3 (en) Novel compounds and methods for inhibiting p53 activity
TW200801031A (en) Steroid nitrooxyderivatives
EP2386639A3 (en) Modified pore-forming protein toxins and use thereof
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
WO2010031708A3 (en) Ortho-aminoanilides for the treatment of cancer
TW200724679A (en) Treatment of disease using an improved regulated expression system
MX2007011486A (es) Formulaciones topicas de antibioticos de acido borinico y sus metodos de uso.
MXPA05010702A (es) Combinacion de un inmunomodulador de celula t de macrolido y un calciferol para el tratamiento de enfermedades de la piel o de enfermedad inflamatoria del intestino.
MX2007005645A (es) Composicion farmaceutica que comprende un inmunomodulador de celulas-t de macrolidos y un agente contra el foto-envejecimiento.
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
BRPI0409207A (pt) combinação de um macrolìdeo e um anestésico local para o tratamento de doenças dermatológicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.